Search
Feed aggregator
Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study
Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study 5/13/2024
Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials
Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials 5/13/2024
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa...
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa... 6/5/2024
FDA Adcomm Votes Against Lykos’ MDMA-Assisted PTSD Therapy
FDA Adcomm Votes Against Lykos’ MDMA-Assisted PTSD Therapy 6/5/2024
Viking Builds Case for NASH Hopeful With Histological Data
Viking Builds Case for NASH Hopeful With Histological Data 6/5/2024
Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI
Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI 6/5/2024
Companies to Watch for Potential M&As in 2024
Companies to Watch for Potential M&As in 2024 6/5/2024
The ABCs of Biopharma This Week: ASCO, BIO and Cancer
The ABCs of Biopharma This Week: ASCO, BIO and Cancer 6/5/2024
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials 4/5/2024
Networking, ADCs and Early Science on the Agenda at AACR 2024
Networking, ADCs and Early Science on the Agenda at AACR 2024 4/5/2024
US National Security, China and Biotechnology in 2024
US National Security, China and Biotechnology in 2024 4/5/2024
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS 4/5/2024
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy 4/5/2024
Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters
Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters 4/5/2024
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B 4/30/2024
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer 4/30/2024
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group 4/30/2024
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program 4/30/2024
World Pharma News
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- New antibody-drug conjugate strategy to block HIV infection
- Rhododendron-derived drugs now made by bacteria
- Lung cancer drug offers a surprising new treatment against ovarian cancer
- Researchers identify promising Alzheimer's disease drug target